Does Horizon Blue Cross Blue Shield of New Jersey Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is the brand name for denosumab 60 mg, a RANK ligand (RANKL) inhibitor that reduces osteoclast activity and slows bone resorption. It is FDA-approved for postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis at high fracture risk, bone loss from hormone ablation in prostate or breast cancer, and glucocorticoid-induced osteoporosis. The FDA originally approved Prolia in June 2010, and the current label remains active on the FDA Drugs database.

Clinical Evidence Behind the Approval

The FREEDOM trial (N=7,808 postmenopausal women) showed denosumab reduced vertebral fracture risk by 68% and hip fracture risk by 40% over 36 months compared with placebo [1]. Those numbers form the basis for guideline support from the Endocrine Society, which states that denosumab is appropriate first-line therapy for patients who cannot tolerate oral bisphosphonates or who have renal impairment (eGFR <35 mL/min/1.73 m²) [2].

The American Association of Clinical Endocrinology (AACE) 2020 guidelines categorize denosumab as a Tier 1 preferred agent for postmenopausal osteoporosis management, particularly for patients with a 10-year FRAX hip fracture probability above 3% or major osteoporotic fracture probability above 20% [3].

Why Coverage Questions Matter

Prolia's list price is approximately $1,400 per injection. Two injections per year yields roughly $2,800 in annual drug costs before any insurance adjustment. Without benefit verification, patients and prescribers can face unexpected denials, treatment gaps, or abrupt discontinuation. Stopping denosumab without transitioning to an oral bisphosphonate raises rebound vertebral fracture risk, a concern documented in a 2017 case series published in Bone [4].

How Horizon BCBS NJ Structures Drug Benefits

Horizon Blue Cross Blue Shield of New Jersey administers multiple plan types, each handling specialty drugs like Prolia differently. The main categories are commercial fully-insured plans, self-funded employer plans, individual and family marketplace plans, Medicare Advantage plans, and Medicaid managed care (NJ FamilyCare) plans.

Commercial and Marketplace Plans

On commercial plans, Prolia is typically placed on Tier 4 or Tier 5 of the specialty drug formulary. Specialty tier cost-sharing commonly runs 20% to 30% coinsurance after deductible, which can still leave a member responsible for $280 to $420 per injection even after plan payment. Prior authorization is required on virtually every commercial Horizon plan.

The standard PA criteria for commercial Horizon plans generally include:

• A DXA scan confirming T-score <-2.5 at the lumbar spine or femoral neck, OR a documented fragility fracture
• Diagnosis of osteoporosis per ICD-10 codes M80 or M81
• Documentation that the patient is postmenopausal, male age 50 or older, or receiving hormone ablation therapy
• Step therapy: a trial of at least one oral bisphosphonate (alendronate, risedronate, or ibandronate) for a minimum of 3 to 6 months, with documented intolerance, contraindication, or inadequate response, unless the prescriber documents a clinical reason to bypass

Step therapy can be bypassed when a patient has an eGFR below 35, esophageal disease precluding oral bisphosphonate use, or a documented severe fragility fracture requiring prompt anabolic or potent antiresorptive therapy.

Medicare Advantage Plans

Horizon offers several Medicare Advantage products in New Jersey, including Horizon Medicare Blue and Horizon Medicare Advantage. Coverage of Prolia under Medicare Advantage mirrors traditional Medicare rules with some plan-level modifications.

Under traditional Medicare, Prolia administered by a physician in an office or infusion center falls under Part B (medical benefit) rather than Part D (pharmacy benefit). The CMS Medicare Benefit Policy Manual confirms that injectable osteoporosis drugs qualify for Part B coverage when a bone fracture related to postmenopausal osteoporosis is present and a physician determines the patient is unable to self-administer [5]. When a patient self-injects at home, coverage moves to Part D.

Medicare Advantage plans must cover everything traditional Medicare covers, per the Medicare Advantage regulations at CMS. This means Prolia injected in the office is covered under the medical benefit with the plan's Part B cost-sharing rules, typically 20% coinsurance after the Part B deductible of $240 in 2024.

NJ FamilyCare (Medicaid Managed Care)

For Horizon NJ Health (Medicaid) members, Prolia coverage follows New Jersey Medicaid preferred drug list criteria. New Jersey Medicaid generally covers denosumab for osteoporosis after bisphosphonate failure. PA requirements are similar to commercial plans: documented diagnosis, DXA evidence, and step therapy documentation. Members enrolled in NJ FamilyCare through Horizon NJ Health should confirm their specific product's formulary tier before prescribing.

Prior Authorization: Step-by-Step Process

Prior authorization for Prolia through Horizon BCBS NJ follows a defined pathway. Understanding each step reduces delays.

Step 1: Obtain the Correct PA Form

Horizon's specialty pharmacy and medical PA forms differ. For office-administered Prolia (Part B or medical benefit), the prescriber submits a Medical Drug Prior Authorization form. For pharmacy-dispensed Prolia, a Pharmacy Prior Authorization form is used. Both are available through Horizon's provider portal at NaviNet or by calling Horizon's Provider Services line at 1-800-624-1110.

Step 2: Compile Clinical Documentation

The prescriber's office should gather:

• A DXA scan report dated within the past 24 months showing T-score and Z-score at lumbar spine and total hip
• Complete medication history showing bisphosphonate trial dates, doses, and reason for discontinuation
• Relevant labs: serum creatinine and calculated eGFR, serum calcium, 25-OH vitamin D level
• Clinical notes documenting fracture history if applicable
• ICD-10 diagnosis codes (M81.0 for age-related osteoporosis in women without current pathological fracture is the most common)

Step 3: Submit and Track

Horizon's standard PA turnaround is 3 business days for non-urgent requests and 72 hours for urgent requests. New Jersey state law, under N.J.A.C. 11:24A, requires health insurers to respond to urgent PA requests within 72 hours and standard requests within 3 business days [6]. A missing PA approval does not mean denial. Members can track PA status through Horizon's member portal or by calling Member Services at the number on their ID card.

Step 4: If Denied, Request a Peer-to-Peer Review

Before filing a formal appeal, the prescribing physician can request a peer-to-peer phone call with Horizon's medical director or reviewing physician. This call often resolves denials when the prescriber can verbally document clinical nuances not captured in the written record. Peer-to-peer calls should be requested within 5 business days of the denial notice for the fastest resolution.

Appealing a Prolia Denial

New Jersey's Insurance Department regulations give members and providers specific appeal rights under the New Jersey Independent Health Care Appeals Program (IHCAP), which requires health plans to complete first-level internal appeals within 30 days for standard requests and 72 hours for urgent cases [6].

Internal Appeal

The first step is an internal appeal filed directly with Horizon. The appeal letter should include:

• A letter of medical necessity from the prescribing physician citing AACE and Endocrine Society guidelines
• Copies of the DXA report and fracture history
• Published clinical evidence: the FREEDOM trial data showing 68% vertebral fracture risk reduction [1] and any patient-specific risk calculation using the WHO FRAX tool, accessible at FRAX via Sheffield [7]
• Documentation of why step therapy was contraindicated or already completed

External Appeal

If Horizon denies the internal appeal, New Jersey law entitles members to request an external appeal through the IHCAP program. An independent review organization reviews the case and issues a binding decision. The New Jersey Department of Banking and Insurance administers this program. External review requests must be filed within 60 days of the final internal denial. Approval rates for external appeals in oncology and specialty drug cases in New Jersey ran approximately 39% in favor of members in recent DOBI annual reports.

Cost-Sharing and Financial Assistance Options

Even with coverage, out-of-pocket costs can be significant. Several programs can lower or eliminate a member's share.

Amgen ASSIST360 Co-Pay Program

Amgen, Prolia's manufacturer, offers a co-pay assistance card through the ASSIST360 program. Eligible commercially insured patients may pay as little as $0 per injection, with Amgen covering up to $13,000 per year in cost-sharing. Medicare beneficiaries are not eligible for manufacturer co-pay cards under federal anti-kickback statutes, but Medicare members may qualify for the Amgen Safety Net Foundation, which provides free medication to qualifying low-income patients. Details are available at Amgen's patient support page, though HealthRX directs readers to confirm program terms directly with Amgen.

Medicare Extra Help (Low Income Subsidy)

Medicare Part D enrollees with limited income may qualify for the Extra Help program, which reduces Part D premiums, deductibles, and co-pays. The Social Security Administration administers Extra Help enrollment. In 2024, full Extra Help beneficiaries pay no more than $4.50 per generic drug or $11.20 per brand drug per month under Part D.

New Jersey Pharmaceutical Assistance to the Aged and Disabled (PAAD)

The PAAD program helps New Jersey residents aged 65 or older, or disabled adults meeting income thresholds, cover prescription costs not fully paid by Medicare. Income limits for 2024 are $34,874 for single applicants and $42,797 for married couples.

What Diagnoses Support Prolia Coverage at Horizon BCBS NJ?

Horizon's medical policy for denosumab coverage aligns with the FDA label and major specialty society guidelines. Covered indications generally include:

Postmenopausal Osteoporosis

The primary indication. Documentation should confirm menopause status (natural or surgical) and at least one of: T-score <-2.5 at any measured site, T-score between -1.0 and -2.5 with a 10-year FRAX major osteoporotic fracture probability ≥20%, or a prior low-trauma fragility fracture. The NIH Osteoporosis and Related Bone Diseases National Resource Center provides patient-facing guidance that clinicians can reference in appeals [8].

Male Osteoporosis

Men with osteoporosis at high fracture risk qualify based on the same DXA thresholds. The Endocrine Society clinical practice guideline on osteoporosis in men supports denosumab as a treatment option after bisphosphonate failure or when bisphosphonates are contraindicated [9].

Glucocorticoid-Induced Osteoporosis (GIOP)

Patients taking prednisone 5 mg or more daily (or equivalent) for 3 months or longer qualify for osteoporosis treatment per ACR GIOP guidelines [10]. For high-risk GIOP patients (prior fragility fracture or T-score <-2.5), the ACR guideline conditionally recommends denosumab as an alternative to oral bisphosphonates, supporting its use in this population.

Bone Loss from Cancer Hormone Ablation

Men with nonmetastatic prostate cancer receiving androgen deprivation therapy and women with breast cancer receiving aromatase inhibitors qualify under Prolia's FDA label. A 2009 NEJM trial (N=1,468) showed denosumab increased lumbar spine bone mineral density by 5.6% at 24 months versus placebo in men on ADT [11]. This trial is available at NEJM and can be cited directly in a PA letter [11].

Prolia vs. Other Osteoporosis Drugs: Coverage Comparison

Understanding how Prolia compares to covered alternatives helps prescribers and patients make informed decisions when a PA is denied.

Oral Bisphosphonates (First-Line Preferred)

Generic alendronate (70 mg weekly) is available for under $10 per month at most NJ pharmacies and requires no PA on Horizon commercial plans. Risedronate and ibandronate are similarly positioned. The AACE 2020 guidelines place oral bisphosphonates as preferred first-line agents due to cost and safety profile, which is why Horizon uses them as step therapy [3].

Zoledronic Acid (Reclast)

Zoledronic acid 5 mg IV once yearly is preferred in patients with GI intolerance to oral agents. It also requires PA but is often approved before Prolia because its annual cost is lower. A NEJM HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fracture risk at 3 years [12].

Romosozumab (Evenity) and Teriparatide (Forteo)

These anabolic agents carry higher list prices ($20,000 or more annually) and face stricter PA criteria on Horizon plans, typically reserved for patients with very high fracture risk or multiple prior treatment failures. Prolia is generally easier to obtain through PA than these agents.

The following clinical decision framework summarizes when Prolia is likely to clear prior authorization on a Horizon BCBS NJ commercial plan versus when additional documentation or step therapy will be required:

| Clinical Profile | PA Likely Approved | Step Therapy Required | |---|---|---| | T-score <-2.5, prior bisphosphonate failure | Yes | No (already completed) | | T-score <-2.5, no prior treatment, eGFR ≥35 | Possibly | Yes, bisphosphonate trial needed | | T-score <-2.5, eGFR <35 | Yes | No (bisphosphonate contraindicated) | | Fragility fracture + T-score <-2.5 | Yes | No (high fracture risk documented) | | ADT or aromatase inhibitor bone loss | Yes | Varies by plan | | GIOP, high-risk profile | Yes | No (ACR guideline supports direct use) |

Monitoring Requirements Horizon May Require for Renewal PA

Prolia PA approvals are not permanent. Renewal authorization, typically required every 12 months, usually requires documentation of:

• Continued clinical indication (osteoporosis remains present)
• No development of severe hypocalcemia (serum calcium should be normal before each injection, per FDA label guidance)
• Dental clearance documentation if the prescriber notes any planned invasive dental procedures (osteonecrosis of the jaw is a known rare adverse event documented in the FDA label)
• Updated DXA scan every 1 to 2 years per standard of care to document treatment response

Vitamin D and calcium adequacy should be confirmed at each renewal. The NIH Office of Dietary Supplements recommends 600 to 800 IU of vitamin D daily for adults 51 to 70 and 70 or older, respectively, and 1,000 to 1,200 mg of elemental calcium daily for women over 50 [13].

Practical Tips for Prescribers Submitting Horizon Prolia PAs

Getting the first submission right shortens approval time significantly. Prescribers should follow these steps before hitting submit:

First, pull the most recent Horizon medical policy for denosumab from the Horizon Provider Resources portal. Policies update quarterly, and criteria change. Second, ensure the DXA report explicitly states T-score values at the femoral neck and lumbar spine. A report that only lists "osteoporosis present" without numeric T-scores is frequently returned incomplete. Third, document the bisphosphonate trial in the clinical notes with start date, stop date, dose, and reason for discontinuation. A pharmacy fill history printed from the patient's pharmacy and included in the submission packet strengthens the record. Fourth, include the calculated FRAX score in the PA letter. FRAX can be calculated free at WHO FRAX and adds quantitative fracture risk data that Horizon reviewers reference against the 20% major osteoporotic fracture threshold. Fifth, if step therapy bypass is being requested, cite the specific contraindication with ICD-10 code and the clinical guideline supporting the bypass.

A complete first submission reviewed by Amgen ASSIST360 program staff (available by calling 1-800-772-6436) shows that fully complete PA packets are approved within 3 business days in the majority of cases for postmenopausal osteoporosis with prior bisphosphonate history. Incomplete packets face an average additional delay of 7 to 10 business days for supplemental information requests.